Abstract: A use of ganoderma fungal RNA molecules, a drug, a drug composition and a delivery carrier are provided. It has been proved that the tRFs derived from the ganoderma traditional Chinese medicine has an obvious inhibiting effect on airway smooth muscle cell phenotype change (proliferation, abnormal secretion and the like) induced by TGF-?1 and AHR, inflammation and remodeling of asthma mice induced by Dermatophagoides pteronyssinus in the experiments of the present disclosure, which suggests that the tRFs derived from the ganoderma traditional Chinese medicine and a pharmaceutical composition can be a brand new medicine for treating asthma. The drug comprises the RNA molecule and a pharmaceutically acceptable carrier, diluent and/or excipient. The present disclosure is helpful for the research and development of asthma treatment drugs and provides reference for the research and development of other respiratory system disease treatment drugs.

Abstract: This invention discloses a medicinal composition includes a non-coding RNA molecule and an antibody targeting a tumor antigen for preventing and/or treating cancer. This invention uses the synergistic combination of a non-coding RNA molecule or its functional variant or homologue, and an antibody targeting a tumor antigen to prevent and/or treat cancer, thereby providing a novel and effective method in preventing and/or treating various cancers.

Abstract: A method of treating a subject suffering from cancer comprising a step of administering an effective amount of a group of double-stranded RNA molecules to the subject, wherein the RNA molecule is isolated or derived from a bacteria of the genus Escherichia. A method of inhibiting growth or proliferation of cancer cells comprising a step of contacting said cells with said RNA molecule; and a pharmaceutical composition for treating cancer comprising said RNA molecule and a pharmaceutically tolerable excipient. Also a double-stranded RNA molecule and a recombinant vector comprising the double-stranded RNA molecule.

Abstract: A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.

Abstract: A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.

Abstract: A compound including a structure of Formula (I) and a preparation method thereof, wherein R1 is —OH, —CH2OH, or —OCOCH3; R2, R3, and R4 are independently —H, —CH3 or —F, and at least one of R2, R3, and R4 is —F. A method for treating a subject suffering from a viral disease includes administering an effective amount of said compound or a solvate thereof to the subject.

Abstract: A method of isolating at least one sphingolipid portion selected from a sphingoid base portion, a ceramide portion, a glycosphingolipid portion or a phosphosphingolipid portion from Cordyceps, in particular from wild-type Cordyceps, allows for obtaining sphingolipid portions having an increased amount of one of sphingoid bases, ceramides, glycosphingolipids or phosphosphingolipids. The sphingolipid portions isolated contained significant amounts of sphingolipids not reported so far, and possess exceptional immunosuppressive activities. A method of treating a subject suffering from an inflammatory disease like an autoimmune disease or an allergic disease includes administering sphingolipids isolated from Cordyceps, in particular from wild-type Cordyceps. A method of treating a subject suffering from an inflammatory disease includes administering certain sphingolipids to the subject.

Abstract: A system and method for scheduling at least one event includes a component module arranged to receive component data regarding a plurality of possible operation decisions, a modelling module arranged to utilise the plurality of operation decisions to construct a Petri net model to simulate a real world system, a scheduling module arranged to utilise the Petri net and variable data regarding the plurality of operation decisions to determine a schedule of events that is feasible subject to a set of predetermined constraints, and an operation module arranged to provide the schedule of events to at least one external device.

Abstract: A method executed by a computer system that transmits a multimedia content through a negative-base number. The method includes generating a binary sequence for the multimedia content, converting the binary sequence into a negative-base number, receiving the negative-base number, retrieving a negative base of the negative base number, calculating the binary sequence based on the negative-base number and the negative base, and obtaining the multimedia content based on the binary sequence.

Abstract: The present invention discloses a method of determining the presence of autoimmune disease with the use of glycan biomarkers. A method of improving the detection sensitivity of trace glycans from a mixture of glycans and a microfluidic chip therefor are also disclosed.

Abstract: A method of identifying a gene associated with a disease or pathological condition of the disease includes: a) obtaining a first group of exome sequences from a first population suffering from the disease or pathological condition and a second group of exome sequences from a second population not having the disease or pathological condition; b) identifying one or more variants in the first group by comparing it with the second group, and optionally with a public database, to generate a first set of variant data; c) applying a variant quality score calibration tool with a truth sensitivity threshold to remove false-positive variants having a sensitivity lower than the threshold and background variants from the first set of variant data so as to obtain a second set of variant data; d) removing synonymous variants from the second set of variant data to obtain a third set of variant data; and e) identifying one or more deleterious variants from the third set of variant data using a gene burden analysis, optionall

Abstract: A method of preparing a crystalline contrast agent for magnetic resonance imaging from a zwitterionic carboxylic pyridyl ligand includes mixing metal ion and the pyridyl ligand and obtaining crystals therefrom. The crystalline contrast agent includes a manganese-organic or gadolinium-organic 3D framework. The crystalline contrast agent is employed in a kit and a pharmaceutically acceptable composition. The method allows for preparing crystalline contrast agents with superior properties with easily available starting materials and with an economic and efficient process. The method allows for preparing crystalline contrast agents with exceptional water-stability and water-solubility, which exhibit high longitudinal relaxivities and with excellent stabilities under physiological conditions and low cytotoxicity. Further provided is a method for in vivo imaging of a subject, in particular a human, comprising administering the crystalline contrast agent to the subject.

Abstract: One embodiment is a method of treating cancer. The method includes administering a therapeutically effective amount of a compound to a patient.

Abstract: A method for treating a subject suffering from refractory rheumatoid arthritis includes the step of administering an effective amount of a quinonemethide triterpenoid or a pharmaceutically tolerable salt, solvate or anhydrate thereof to the subject. Also is a method for inducing autophagy in a synovial fibroblast, and a method of inducing calcium mobilization in a synovial fibroblast. Further a pharmaceutical composition includes an effective dose of a quinonemethide triterpenoid and an anti-arthritis compound. The quinonemethide triterpenoid is suitable to treat refractory rheumatoid arthritis (RA) in particular ABC-protein-dependent RA and apoptosis-deficient RA. The quinonemethide triterpenoid also possesses significant inhibitory effects on the growth of synovial fibroblasts, in particular modulating the calcium homeostasis in multidrug-resistant rheumatoid arthritis synovial fibroblasts.

Abstract: Controlling operation of a converter circuit regulating power transfer between first and second voltage sources includes comparing a detected power value in the converter circuit with a power command value; determining a converter gain based on detected first and second voltage levels of the first and second voltage sources; and determining operation signals for transmitting to switches in the converter circuit during a steady state to control switching time and duration. When the detected power value differs from the power command value, the method includes determining values of two or more variables associated with adjustment of switching time and duration based on the detected first and second voltage levels; and determining operation signals to transmit to the switches during a power transition state based on the determined values of the two or more variables to adjust switching time and switching duration of the switches, thereby regulating power transition.

Abstract: A system and method of controlling a cluster tool apparatus, wherein the cluster tool includes one or more processing modules and a robot that is configured to move a semiconductor product to and from the one or more processing modules, the cluster tool configured for processing semiconductor products. The method of controlling the cluster tool apparatus to perform a processing cycle includes receiving a plurality of system parameters from a user interface, wherein the system parameters relate to one or more processing steps of the processing cycle, determining a schedule for performing the processing cycle utilizing the one or more processing modules, wherein the schedule being determined based on a semiconductor product residency parameter.

Abstract: A method improves information security by generating a key with which a first multimedia content is encrypted into a second multimedia content. The method generates a first representation for the first multimedia content and a second representation for the second multimedia content on a complex plane, and improves the information security by generating the key by determining a relationship between the first representation and the second representation on the complex plane such that the first multimedia content is encrypted into the second multimedia content with the relationship as the key.

Abstract: Example embodiments include a method that improves calculations of surface roughness that map a planetary surface. The method includes calculating a V-system matrix with a size of ?×? in an interval [0,1]; transforming the V-system matrix into an orthogonal matrix; improving calculations of the surface roughness of the planetary surface by calculating the surface roughness of a digital elevation model generated from data captured from the planetary surface; and generating a map of the planetary surface based on the surface roughness.

Abstract: The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.

Abstract: A method and a device for information system access authentication are disclosed. The method includes: performing anonymous authentication to a random verification code generated according to a login request for accessing an information system of a client, and authenticating acquired user name and password information when the anonymous authentication is successful. The device includes an verification code authentication module and a user name and password authentication module connected to the verification code authentication module, wherein the verification code authentication module is configured to perform anonymous authentication to a random verification code generated according to a login request for accessing an information system of client; and the user name and password authentication module is configured to authenticate acquired user name and password information when the anonymous authentication is successful.